Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program
|
|
- Lionel Dean
- 5 years ago
- Views:
Transcription
1 Moore online supp 1 Online Data Supplement Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program Wendy C. Moore, MD, Deborah A. Meyers, PhD, Sally E. Wenzel, MD, W. Gerald Teague, MD, Huashi Li, MS, Xingnan Li, PhD, MS, Ralph D Agostino, Jr., PhD, Mario Castro, MD, Douglas Curran-Everett, PhD, Anne M. Fitzpatrick, PhD, Benjamin Gaston, MD, Nizar N. Jarjour, MD, Ronald Sorkness, PhD, William J. Calhoun, MD, Kian Fan Chung, MD, Suzy A.A. Comhair, PhD, Raed A. Dweik, MD, Elliot Israel, MD, Stephen P. Peters, MD, PhD, William W. Busse, MD, Serpil C. Erzurum, MD, Eugene R. Bleecker, MD for the National Heart Lung Blood Institute s Severe Asthma Research Program.
2 Moore online supp 2 FIGURE E1. FIGURE E1. Reduction of the original 628 variables in the SARP database. * Numbers correspond to variable numbers in Table E2. The 17 composite variables from the questionnaire data incorporate answers from 63 individual questions. The 34 final variables in the cluster analysis include 23 variables from the questionnaire data, 6 related to lung function and 5 markers of atopy. Following the cluster analysis, stepwise discriminant analysis identified 11 significant predictors of cluster assignment. Three of these variables (Baseline and Maximal FEV1 % predicted, age of disease onset) were used in the Tree analysis.
3 Moore online supp 3 TABLE E1. Generation of a Variable: Frequency/Severity of HCU in Past year. Rank Weight of Rank Questions * n Severe Asthma Chronic Oral Steroids FEV1% pred Maximum FEV% 0 0 None reported % 2% 81% 92% urgent visit/yr 70 40% 4% 78% 89% 2 4 ED past year 83 42% 5% 77% 88% OCS burst/yr % 32% 67% 80% 4 8 Hospitalization past year 81 88% 36% 65% 81% 5 10 ICU past year 59 93% 42% 66% 84% n=856 for this table (composites were developed prior to excluding children < 12 years of age from the analysis). * Questions used to generate the composite variable are from two separate forms. Subjects receive the highest rank based on their answers (i.e. each subject appears only once). Weight of ranks within a composite variable are on a scale of 0-10 (each subject gets the weight assigned to their rank). Five variables are now one variable Frequency/Severity of HCU in Past year and each subject has a score. The four columns on the right verify that the composite variable effectively discriminates severity of health care utilization based on disease severity, need for oral corticosteroids and lung function. Severe asthma as defined by the ATS workshop on severe asthma (11).
4 Moore online supp 4 TABLE E2. List of Variables used in Cluster Analysis Variable Number Type of Data Variable Name Key 1 Binary Gender Male/Female 2 Categorical Race Caucasian/AA/Other 3 Continuous BMI 4 Age at Enrollment Continuous 5 Age of Asthma Onset Ages 6 Asthma Duration Continuous Baseline Lung Function Continuous Maximum Max or Best Lung Function Continuous Atopy Medication Use Health Care Utilization Asthma Symptoms Patterns of Skin Test Responses Triggers FEV1 % predicted FVC % predicted FEV1/FVC FEV1 % predicted FVC % predicted Maximal % change in FEV1 Pre-bronchodilator > 6 hours withholding of bronchodilators Post-bronchodilator Best values after 6-8 puffs of albuterol Number of Positive Skin Tests Range 0-12 Corticosteroid Use Total Number of Controllers Type of Controllers Beta-agonist Frequency Score Frequency/Severity past year Intensity/ ICU ever in lifetime General Symptoms Score Symptoms with Activities Cats/Dogs Dust Mites/Cockroach Molds Pollens Severity of Allergy Symptoms Aspirin Sensitivity/ Nasal Polyps Sinusitis/Sinus Surgery Bronchitis/Pneumonia GERD and HTN Number of positive tests for each type of allergen 30 Co-morbidity: 31 Parental Asthma 32 Family History Siblings with Asthma 33 Tobacco Exposure: Passive/Remote 34 Women s Hormone Exposure
5 Moore online supp 5 FIGURE E2. FIGURE E2. Dendrogram. Using Wald s minimum-variance hierarchical clustering method and an agglomerative (bottom-up) approach, 726 subjects were clustered to a single final group. At each generation of clusters, samples were merged into larger clusters to minimize the within-cluster sum of squares or maximize between-cluster sum of squares. With successive clustering, 5-6 groups became obvious, although the 6 th group was quite small (n=31, a subgroup of Cluster 5) and we chose to stop at five clusters instead.
6 Moore online supp 6 TABLE E3. Demographics and Clinical Characteristics of Subjects Classified by Severity * Mild Moderate Severe Number of Subjects P-value Age at Enrollment (yrs) 31 (12) 38 (12) 41 (15) < Gender (% female) 73% 61% 63% Race (% Cauc /AA/Other) 67/27/6 61/30/9 62/29/ Body Mass Index > 30 (BMI) 26% 39% 47% < Age of Asthma Onset (yrs) 13 (13) 15 (14) 16 (16) 0.65 Asthma Duration (yrs) 18 (12) 23 (14) 25 (14) < Baseline Lung Function FEV1 % predicted 94 (11) 66 (13) 62 (21) < FVC % predicted 100 (12) 81 (15) 77 (20) < FEV1/FVC 0.79 (0.07) 0.67 (0.10) 0.65 (0.13) < Maximal Lung Function FEV1 % predicted 103 (10) 82 (13) 77 (21) < FVC % predicted 104 (12) 92 (15) 90 (18) < % change in FEV1 10 (8) 19 (18) 21 (21) < PC20 Methacholine, mg/ml 1.51 (0.65) 0.85 (0.65) 0.79 (0.77) F E NO, ppb 28 (0.37) 30 (0.35) 27 (0.39) 0.60 Atopy Status Total IgE, IU/ml 110 (0.72) 120 (0.62) 120 (0.75) 0.83 % with 1 positive test 83% 86% 67% < Asthma Medications LTRA 21% 22% 53% < ICS 55% 62% 98% < LABA 44% 50% 89% < OCS 3% 3% 48% < Xolair 0% 0% 14% < Numeric data expressed as Mean (SD) or Geometric Mean (log 10 SD) * Severity defined by prebronchodilator FEV1 and inhaled corticosteroid (ICS) use; Mild asthma = FEV1 80% predicted on no or low doses of ICS; Moderate asthma = FEV1 < 80% predicted on low to moderate doses of ICS; Severe = Meets ATS workshop definition of severe asthma. Pre-bronchodilator values with > 6 hours withhold of bronchodilators. Post-bronchodilator values after 6-8 puffs of albuterol. Subjects with FEV1 < 55% predicted pre-testing were excluded from methacholine challenge.
7 Moore online supp 7 TABLE E4. Geographic Distribution of Subjects in Clusters by Clinical Center Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Number of Subjects Brigham & Women s Hospital Cleveland Clinic Emory University Imperial College, UK University of Pittsburgh * University of Virginia Wake Forest University University of Wisconsin Washington University * Includes subjects studied at National Jewish Hospital 8/2001 to 6/2006.
8 Moore online supp 8 FIGURE E3A. FIGURE E3B. % P< P< % of Subjects % of Subjects Figure E3A and B. Frequency of reported asthma symptoms (Fig. 3A) and albuterol use (Fig. 3B) in past 3 months as assessed by composite variable scores. Symptoms and albuterol use increase in frequency from Cluster 1 to 5. The mildest clusters (1 and 2) report similar bronchodilator use and symptoms suggesting a more active lifestyle may lead to albuterol use (pre-exercise) in these younger groups. Most of the subjects in Clusters 4 and 5 report daily symptoms and albuterol use that is likely due to their severe airflow obstruction at baseline. The majority of Cluster 3 subjects also report daily symptoms despite their near normal lung function suggesting that obesity may play a role in their daily shortness of breath. light grey bars = less than monthly, dark gray bars = weekly, black bars = daily.
9 Moore online supp 9 TABLE E5. Clinical Characteristics of Subjects in Cluster 6 Cluster 5 Cluster 6 Number of Subjects Age at Enrollment (yrs) 52 (10) 42 (11) Gender (% female) 62% 65% Race (% Cauc /AA/Other) 69/18/13 65/26/10 Body Mass Index 31 (7) 32 (8) Age of Asthma Onset (yrs) 23 (16) 15 (13) Asthma Duration (yrs) 30 (16) 27 (12) Baseline Lung Function FEV1 % predicted 43 (12) 45 (17) FVC % predicted 59 (13) 62 (16) FEV1/FVC 0.57 (0.11) 0.58 (0.13) Maximal Lung Function FEV1 % predicted 55 (12) 65 (16) FVC % predicted 72 (13) 85 (13) Change in % predicted FEV1 34 (29) 54 (40) F E NO, ppb 46 (46) 44 (43) Total IgE, IU/ml 204 (269) 329 (625) Numeric data expressed as Mean (SD) Pre-bronchodilator values with > 6 hours withhold of bronchodilators. Post-bronchodilator values after 6-8 puffs of albuterol.
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationIdentification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program Wendy C. Moore 1,2, Deborah A. Meyers 1,2, Sally E. Wenzel 2, W. Gerald Teague 2, Huashi Li 1, Xingnan Li
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationPredicting response to triamcinolone in severe asthma by machine learning: solving the Enigma
Page 1 of 5 Predicting response to triamcinolone in severe asthma by machine learning: solving the Enigma Kian Fan Chung National Heart & Lung Institute, Imperial College London & Royal Brompton and Harefield
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationUSAID Health Care Improvement Project
IMPROVEMENT OBJECTIVE: Decrease asthma/copd morbidity and mortalityin affected adults and children through improved quality of asthma/copd case-management (ambulatory & hospital) Cross-cutting ambulatory
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationKEY WORDS airflow limitation, airway hyperresponsiveness, airway inflammation, airway lability, peak expiratory flow rate
Allergology International. 2013;62:343-349 DOI: 10.2332 allergolint.13-oa-0543 ORIGINAL ARTICLE Stratifying a Risk for an Increased Variation of Airway Caliber among the Clinically Stable Asthma Atsushi
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationKey words: Allergic sensitization, asthma, severe asthma, asthma guidelines, children, cluster analysis, lung function, phenotype
Heterogeneity of severe asthma in childhood: Confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program Anne
More informationPediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest:
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationAn Insight into Allergy and Allergen Immunotherapy Co-morbidities of allergic disease
An Insight into Allergy and Allergen Immunotherapy Co-morbidities of allergic disease Carmen Vidal Athens, September 11, 2014 Pucci S & Incorvaia C, 2008; 153:1-2 1. The major player in driving the immune
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationAsthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
More informationΑνασκόπηση Βιβλιογραφίας στο Άσθμα: Τα 5 κορυφαία άρθρα σχετικά με τους φαινοτύπους του άσθματος του τελευταίου έτους
Ανασκόπηση Βιβλιογραφίας στο Άσθμα: Τα 5 κορυφαία άρθρα σχετικά με τους φαινοτύπους του άσθματος του τελευταίου έτους Στυλιανός Κ. Βιττωράκης MD, PhD. Πνευμονολόγος, Χανιά Ερέτρια, 16 Μαρτίου 2014 Exploring
More informationWorld Allergy Forum Symposium: An Update on Severe Asthma
World Allergy Forum Symposium: An Update on Severe Asthma XXVII Congress of the European Academy of Allergology and Clinical Immunology Monday, 9 June 2008 15.30 17.00 Barcelona International Convention
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationThe IL6R variation Asp 358 Ala is a potential modifier of lung function in subjects with asthma
The IL6R variation Asp 358 Ala is a potential modifier of lung function in subjects with asthma Gregory A. Hawkins, PhD, a,b Mac B. Robinson, PhD, a Annette T. Hastie, PhD, a,b Xingnan Li, PhD, a,b Huashi
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationWEBINAR. Difficult-to-treat and severe asthma: changing the paradigm
WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationasthma, order-made medicine, phenotypes 2.1 Cluster analysis by Haldar et al.
Received: 8 June 2015 Accepted: 25 February 2016 DOI: 10.1002/jgf2.7 REVIEW ARTICLE Asthma phenotypes Masahiro Hirose MD, PhD Takahiko Horiguchi MD, PhD Department of Respiratory Medicine II, Fujita Health
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Pediatric Asthma: Assessment & Control August 2, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Pediatric Asthma: Assessment & Control August 2, 2017 12:00pm 1:00pm Allyson S. Larkin, MD Assistant Professor of Pediatrics
More informationCurrent Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
More informationPredictors of obstructive lung disease among seafood processing workers along the West Coast of the Western Cape Province
Predictors of obstructive lung disease among seafood processing workers along the West Coast of the Western Cape Province Adams S 1, Jeebhay MF 1, Lopata AL 2, Bateman ED 3, Smuts M 4, Baatjies R 1, Robins
More informationAsthma 2015: Establishing and Maintaining Control
Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationEFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Severity Assessment, Guidelines, and New Therapeutic Options
Educational Objectives EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP President-Elect, American College of Allergy, Asthma & Immunology Medical Director,
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationSevere Asthma Phenotypes in Children
Severe Asthma Phenotypes in Children Andy Liu, MD Pulmonary Section The Breathing Institute Children s Hospital Colorado University of Colorado Denver School of Medicine The National Jewish Experience:
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationERJ Express. Published on December 12, 2013 as doi: /
ERJ Express. Published on December 12, 2013 as doi: 10.1183/09031936.00202013 International ERS/ATS Guidelines on Definition, Evaluation, and Treatment of Severe Asthma 2013 International ERS/ATS Guidelines
More information2. Does the patient have chronic urticaria? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationPediatric and Adult. Disclosure. Asthma. Learning Objectives. EPR-3: What s Changed? Asthma: Pediatric and Adult
Asthma: Pediatric and Adult Americo D. Fraboni, MD, FAAFP Assistant Clinical Professor Department of Family Practice & Community Health University of Minnesota Medical School Minneapolis, Minnesota Disclosure
More informationHow to distinguish between uncontrolled and severe asthma
How to distinguish between uncontrolled and severe asthma Watch patient using their inhaler. Discuss adherence and barriers to use Compare inhaler technique with a devicespecific checklist, and correct
More informationAsthma is a heterogeneous airway disease. Identification of asthma clusters in two independent Korean adult asthma cohorts
Eur Respir J 2013; 41: 1308 1314 DOI: 10.1183/09031936.00100811 CopyrightßERS 2013 Identification of asthma clusters in two independent Korean adult asthma cohorts Tae-Bum Kim*,"", An-Soo Jang #,"", Hyouk-Soo
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationFungal exposure, atopy and asthma exacerbations in Puerto Rican children ONLINE DATA SUPPLEMENT
Fungal exposure, atopy and asthma exacerbations in Puerto Rican children ONLINE DATA SUPPLEMENT Joshua Blatter, MD 1, Erick Forno, MD, MPH 1, John Brehm, MD, MPH 1, Edna Acosta- Pérez, PhD 2, María Alvarez,
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationGetting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital
Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com } Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate)
More informationTHE ROLE OF THE IL4/13 PATHWAY IN THE GENETICS OF ASTHMA SEVERITY. REBECCA E. SLAGER, PhD. A Thesis Submitted to the Graduate Faculty of
THE ROLE OF THE IL4/13 PATHWAY IN THE GENETICS OF ASTHMA SEVERITY By REBECCA E. SLAGER, PhD A Thesis Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in
More informationPresented by the California Academy of Family Physicians 2013/California Academy of Family Physicians
Family Medicine and Patient-Centered Asthma Care Presented by the California Academy of Family Physicians Faculty: Hobart Lee, MD Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine
More informationComplements asthma therapy NOT a CURE for Severe. Non pharmacologic treatment of asthma. limits the ability of the airways to constrict.
Bronchial Thermoplasty Karla Provost Pulmonary and Critical Care Medicine 2015 What is Bronchial Thermoplasty Non pharmacologic treatment of asthma Outpatient procedure performed over 3 treatment sessions
More informationWhat is Severe Persistent Asthma? What is Bronchial Thermoplasty Non pharmacologic treatment of asthma
Objectives BT defined What is Severe Persistent Asthma Case Study introduction How is BT performed Pre-op, PACU and Discharge care Who does it work for the criteria for BT Brief overview of BT results
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationEffective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017
Protocol Title: Adult Asthma Protocol Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017 1 Purpose & Objective This protocol provides evidence-based
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationRecent asthma exacerbations: A key predictor of future exacerbations
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/6873954 Recent asthma exacerbations: A key predictor of future exacerbations Article in Respiratory
More informationONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS
R2 (REVISED MANUSCRIPT BLUE 200208-877OC) ONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS Mario Castro, M.D., M.P.H. Nina A. Zimmermann R.N. Sue
More informationMAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER 16 year old female with h/o moderate persistent asthma presents to the ED after 6 hours of difficulty breathing, cough, and wheezing
More informationAND COPD ADVANCES IN COMBINATION THERAPY FOR ASTHMA. Jan Lotvall. Editor. Krefting Research Centre, University of Gothenburg,
ADVANCES IN COMBINATION THERAPY FOR ASTHMA AND COPD Editor Jan Lotvall Krefting Research Centre, University of Gothenburg, Sweden A Wiley Sons, Ltd., Publication Contents Contributors xi Preface 1 Similarities
More informationNIOSH FIELD STUDIES ON DAMPNESS AND MOLD AND RELATED HEALTH EFFECTS
NIOSH FIELD STUDIES ON DAMPNESS AND MOLD AND RELATED HEALTH EFFECTS Jean Cox-Ganser, Ph.D. Division of Respiratory Disease Studies The findings and conclusions in this presentation are those of the author
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationSergio Bonini. Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy.
Assessment of EIA in the community and in athletes: the role of standardized questionnaires Sergio Bonini Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy se.bonini@gmail.com
More informationAsthma and obesity, implications for airway inflammation and Bronchial Hyperresponsiveness
Asthma and obesity, implications for airway inflammation and Bronchial Hyperresponsiveness Fernando Holguin MD MPH Asthma Institute University of Pittsburgh Obesity Trends* Among U.S. Adults BRFSS, 1990,
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationI have no perceived conflicts of interest or commercial relationships to disclose.
ASTHMA BASICS Michelle Dickens RN FNP-C AE-C Nurse Practitioner/Certified Asthma Educator Ferrell Duncan Allergy/Asthma/Immunology Coordinator, CoxHealth Asthma Center DISCLOSURES I have no perceived conflicts
More informationAsthma Update I have no professional or personal financial conflicts of interest to disclose.
Asthma Update 2018 Disclosures Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center I have
More informationAsthma Update Jennifer W. McCallister, MD, FACP, FCCP
Asthma Update 2018 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center Disclosures I have
More informationAsthma Assessment & Review
ASTHMA RESOURCE PACK Section 5B Asthma Assessment & Review In this section: 1. Primary Care initial assessment and review Asthma Resource Pack Section 5B: Asthma Assessment & Review Version 3.0 Last Updated:
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationStep up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible
12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationAsthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study
Silkoff et al. Respiratory Research (2015) 16:142 DOI 10.1186/s12931-015-0299-y RESEARCH Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT)
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More information